TSHA

1.61

1.83% -0.03

Dopo l'orario di chiusura: 1.66 0.05 +3.11%

Taysha Gene Therapies Inc (TSHA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.64

Aprire:

$1.64

Volume 24 ore:

1.63M

Relative Volume:

0.53

Capitalizzazione di mercato:

$329.96M

Reddito:

$12.87M

Utile/perdita netta:

$-114.34M

Rapporto P/E:

-1.8621

EPS:

-0.8646

Flusso di cassa netto:

$-79.23M

1 W Prestazione:

-1.23%

1M Prestazione:

+5.23%

6M Prestazione:

-28.76%

1 anno Prestazione:

-36.11%

Intervallo 1D:

$1.60

$1.71

Intervallo di 1 settimana:

$1.58

$1.74

Portata 52W:

$1.19

$4.32

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Nome

Taysha Gene Therapies Inc

Settore

Healthcare (1169)

Industria

Biotechnology (678)

Telefono

(214) 612-0000

Indirizzo

3000 PEGASUS PARK DRIVE, DALLAS

Dipendente

Cinguettio

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

TSHA's Discussions on Twitter

Confronta TSHA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TSHA Taysha Gene Therapies Inc	1.61	329.96M	12.87M	-114.34M	-79.23M	-0.8646
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-06-27	Iniziato	BMO Capital Markets	Outperform
2024-04-09	Iniziato	Piper Sandler	Overweight
2023-02-01	Downgrade	Jefferies	Buy → Hold
2023-01-27	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2022-11-09	Downgrade	Goldman	Buy → Neutral
2022-03-09	Iniziato	Robert W. Baird	Outperform
2022-03-01	Iniziato	Wells Fargo	Overweight
2022-02-18	Iniziato	SMBC Nikko	Outperform
2021-12-16	Iniziato	Guggenheim	Buy
2021-07-16	Iniziato	Needham	Buy
2021-06-24	Iniziato	Truist	Buy
2021-06-15	Iniziato	BTIG Research	Buy
2021-06-09	Iniziato	Wedbush	Outperform
2021-06-08	Iniziato	JMP Securities	Mkt Outperform
2021-05-19	Iniziato	Cantor Fitzgerald	Overweight
2021-05-11	Ripresa	Jefferies	Buy
2021-02-24	Iniziato	William Blair	Outperform
2021-01-05	Iniziato	Oppenheimer	Outperform
2020-10-19	Iniziato	Chardan Capital Markets	Buy
2020-10-19	Iniziato	Goldman	Buy
2020-10-19	Iniziato	Jefferies	Buy
2020-10-19	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie

Feb 21, 2025

Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World

Feb 21, 2025

Feb 20, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire

Feb 20, 2025

Feb 19, 2025

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times

Feb 19, 2025

Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan

Feb 19, 2025

Feb 17, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World

Feb 17, 2025

Feb 15, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World

Feb 15, 2025

Feb 14, 2025

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat

Feb 14, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Feb 14, 2025

Feb 12, 2025

Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World

Feb 12, 2025

Feb 07, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025